CUFinder

Alex Kintu

Alex Kintu

Harvard University

H-index: 12

North America-United States

Contact Alex Kintu

About Alex Kintu

Alex Kintu, With an exceptional h-index of 12 and a recent h-index of 12 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Drug Development - Virology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Gender affirming hormones do not affect the exposure and efficacy of F/TDF or F/TAF for HIV preexposure prophylaxis: a subgroup analysis from the DISCOVER trial

Facilitating next‐generation pre‐exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the Forum HIV Prevention Trial Design Project

2079. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (eStimating hIv incidEnce amoNg Agyw) Study in Uganda

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)

Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Comparison of HIV Incidence as Determined by Different Recency Assays in Ugandan Women

Proximate and distal factors associated with the stall in the decline of adolescent pregnancy in Uganda

854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Alex Kintu Information

University

Position

Doctoral Candidate in Global Health

Citations(all)

744

Citations(since 2020)

456

Cited By

419

hIndex(all)

12

hIndex(since 2020)

12

i10Index(all)

12

i10Index(since 2020)

12

Email

University Profile Page

Google Scholar

Alex Kintu Skills & Research Interests

Drug Development - Virology

Top articles of Alex Kintu

Gender affirming hormones do not affect the exposure and efficacy of F/TDF or F/TAF for HIV preexposure prophylaxis: a subgroup analysis from the DISCOVER trial

Transgender Health

2024/2/1

Jan De Jong
Jan De Jong

H-Index: 0

Peter Ruane
Peter Ruane

H-Index: 8

Facilitating next‐generation pre‐exposure prophylaxis clinical trials using HIV recent infection assays: a consensus statement from the Forum HIV Prevention Trial Design Project

2023/7

Fei Gao
Fei Gao

H-Index: 40

James P Hughes
James P Hughes

H-Index: 19

Jeffrey Murray
Jeffrey Murray

H-Index: 2

Joseph Lau
Joseph Lau

H-Index: 70

Veronica Miller
Veronica Miller

H-Index: 23

Jared Baeten
Jared Baeten

H-Index: 54

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Alex Kintu
Alex Kintu

H-Index: 6

Frances Cowan
Frances Cowan

H-Index: 35

Brian Rice
Brian Rice

H-Index: 5

Elizabeth Russell
Elizabeth Russell

H-Index: 2

Wen Zeng
Wen Zeng

H-Index: 5

Sandra Mccoy
Sandra Mccoy

H-Index: 19

2079. Comparison of Recency Assays to Estimate HIV Incidence in the SIENA (eStimating hIv incidEnce amoNg Agyw) Study in Uganda

Open Forum Infectious Diseases

2022/12/1

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Jared Baeten
Jared Baeten

H-Index: 54

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)

PloS one

2022/6/3

Alex Kintu
Alex Kintu

H-Index: 6

Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Presented at BHIVA Spring Conference

2022/4/20

Peter Ruane
Peter Ruane

H-Index: 8

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Alex Kintu
Alex Kintu

H-Index: 6

Jared Baeten
Jared Baeten

H-Index: 54

Comparison of HIV Incidence as Determined by Different Recency Assays in Ugandan Women

2022

Alex Kintu
Alex Kintu

H-Index: 6

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Jared Baeten
Jared Baeten

H-Index: 54

Proximate and distal factors associated with the stall in the decline of adolescent pregnancy in Uganda

BMC Public Health

2021/12

David Canning
David Canning

H-Index: 52

854. Long-term Outcomes of Participants on F/TAF for Pre-Exposure Prophylaxis: Results for 144 Weeks of Follow-Up in the DISCOVER Trial

Open Forum Infectious Diseases

2021/11/1

Peter Ruane
Peter Ruane

H-Index: 8

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Alex Kintu
Alex Kintu

H-Index: 6

Jared Baeten
Jared Baeten

H-Index: 54

848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for …

Open Forum Infectious Diseases

2021/11/1

Alex Kintu
Alex Kintu

H-Index: 6

Jared Baeten
Jared Baeten

H-Index: 54

Outcomes of participants switching from F/TDF to F/TAF for PrEP: week 48 results from the DISCOVER open label phase

International AIDS Society Conference, Virtual

2021/7/1

Alex Kintu
Alex Kintu

H-Index: 6

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Jared Baeten
Jared Baeten

H-Index: 54

Amanda Clarke
Amanda Clarke

H-Index: 18

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results …

The Lancet HIV

2021/7/1

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Amanda Clarke
Amanda Clarke

H-Index: 18

Kenneth Mayer
Kenneth Mayer

H-Index: 15

Sheldon Morris
Sheldon Morris

H-Index: 27

Andrew Petroll
Andrew Petroll

H-Index: 14

Peter Ruane
Peter Ruane

H-Index: 8

Laura Salazar
Laura Salazar

H-Index: 33

Gary Sinclair
Gary Sinclair

H-Index: 7

Magdalena Sobieszczyk
Magdalena Sobieszczyk

H-Index: 24

Stephen Taylor
Stephen Taylor

H-Index: 31

Noncommunicable Disease (NCD) strategic plans in low-and lower-middle income Sub-Saharan Africa: framing and policy response

Global Health Action

2020/12/31

Christopher Noble
Christopher Noble

H-Index: 1

Matthew M Coates
Matthew M Coates

H-Index: 20

Andrew Marx
Andrew Marx

H-Index: 2

Gene Bukhman
Gene Bukhman

H-Index: 23

Burden of non-communicable diseases from infectious causes in 2017: a modelling study

The Lancet Global Health

2020/12/1

Matthew M Coates
Matthew M Coates

H-Index: 20

Gene Bukhman
Gene Bukhman

H-Index: 23

Safety and efficacy of F/TAF and F/TDF for PrEP in DISCOVER participants taking F/TDF for PrEP at baseline

Presented at IDWeek

2020/10/21

Amanda Clarke
Amanda Clarke

H-Index: 18

Alex Kintu
Alex Kintu

H-Index: 6

Ramin Ebrahimi
Ramin Ebrahimi

H-Index: 22

Integrating care for non‐communicable diseases into routine HIV services: key considerations for policy design in sub‐Saharan Africa

Journal of the International AIDS Society

2020/6

David Guwatudde
David Guwatudde

H-Index: 24

Stéphane Verguet
Stéphane Verguet

H-Index: 33

Cost‐effectiveness analysis of integrating screening and treatment of selected non‐communicable diseases into HIV/AIDS treatment in Uganda

Journal of the International AIDS Society

2020/6

David Guwatudde
David Guwatudde

H-Index: 24

Stéphane Verguet
Stéphane Verguet

H-Index: 33

The Impact of HIV and Antiretroviral Therapy on Cardiovascular Diseases in Sub-Saharan Africa

2020

See List of Professors in Alex Kintu University(Harvard University)